Clinically significant gastrointestinal disorders.
Urinalysis: o No clinically significant abnormalities
Known significant clinically significant gastrointestinal disease
History of osteonecrosis of the hip or have evidence of structural bone abnormalities in the proximal femur on MRI scan that are symptomatic and clinically significant.
Clinically significant gastrointestinal disorders
Patients with clinically significant abnormalities on urinalysis at < 14 days prior to randomization.
Significant gastrointestinal disease
Participants with any clinically significant gastrointestinal abnormalities that may alter absorption
Urinalysis: No clinically significant abnormalities
Urinalysis: No clinically significant abnormalities
Clinically significant abnormalities found on an ECG.
Clinically significant gastrointestinal disorders
Clinically significant abnormalities in laboratory test results (including complete blood count, chemistry panel including electrolytes, and urinalysis)
Any Grade 3 or higher lab abnormalities should be discussed and approved by the Medical Monitor prior to enrollment (even if not considered clinically significant);
Significant gastrointestinal abnormalities,
Urinalysis: No clinically significant abnormalities.
Significant gastrointestinal abnormality.
Urinalysis: No clinically significant abnormalities.
Patient has no clinically significant abnormalities on urinalysis results.
No Severe or Chronic medical conditions including gastrointestinal abnormalities or significant cardiac history
Clinically significant gastrointestinal abnormalities
History or presence of clinically relevant cardiovascular abnormalities as per investigator assessment.
History of osteonecrosis of the hip or have evidence of structural bone abnormalities in the proximal femur on MRI scan that are symptomatic and clinically significant.
Any clinically significant gastrointestinal abnormalities, which may impair intake, transit or absorption of the study drug, such as the inability to take oral medication in tablet form
Subject has no clinically significant abnormalities in urinalysis results (obtained ? 14 days prior to starting Cycle 1 Day 1).
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding
Clinically significant gastrointestinal abnormalities that may affect absorption of investigational products
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding.
Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product.
Patient has a urinalysis obtained (=< 14 days prior to randomization) and the results are deemed not clinically significant by the investigator
History or presence of clinically relevant cardiovascular abnormalities
Urinalysis: No clinically significant abnormalities
Clinically significant gastrointestinal abnormalities, apart from gastric cancer, including uncontrolled inflammatory gastrointestinal diseases
Clinically significant abnormalities of glucose metabolism.
Clinically significant GI abnormalities that may affect absorption of investigational product.
Clinically significant gastrointestinal disorder
Clinically significant comorbid medical conditions or lab abnormalities
Liver enzymes without clinically significant abnormalities after review by the study physicians
Clinically significant gastrointestinal malabsorption syndrome
